Drug Trial Radar · NCT01600014
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
463
Actual
Start
May 2012
Primary completion
Feb 2014
Study completion Feb 2014
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- May 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.
Conditions
- Actinic Keratosis
Interventions
Ingenol mebutate gel, 0.015%Drug
Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
Vehicle gelDrug
Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Complete Clearance of AKs 8 Weeks After RandomisationTime frame: 8 weeks after randomisation
Locations
13 sites in 5 countries. Site status is shown where the registry gives one.
St John of God Dermatology
Subiaco, Australia
Stratica Medical
Edmonton, Alberta, Canada
Skin Care Centre
Vancouver, British Columbia, Canada
Dermadvances Research
Winnipeg, Manitoba, Canada
Durondel C.P. Inc./Dermatology Clinic
Moncton, New Brunswick, Canada
UltraNova Skincare
Barrie, Ontario, Canada
SKiN Centre for Dermatology
Peterborough, Ontario, Canada
Windsor Clinical Research Inc.
Windsor, Ontario, Canada
Innovaderm Research Inc.
Montreal, Quebec, Canada
Centre de Recherche Dermatologique
Québec, Quebec, Canada
CHU de Nantes
Nantes, Loire-Atlantique 6, France
Universitätsklinikum Tübingen
Tübingen, Germany
Central Manchester University Hosptial
Manchester, Greater Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.